Valuation and EarningsThis table compares 20/20 Biolabs and its competitors top-line revenue, earnings per share and valuation. Get 20/20 Biolabs alerts:Gross Revenue Net Income Price/Earnings Ratio 20/20 Biolabs $1.84 million -$3.74 million -1.63 20/20 Biolabs Competitors $20.32 billion $277.67 million -234.8320/20 Biolabs’ competitors have higher revenue and earnings than 20/20 Biolabs. Analyst RecommendationsSell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 20/20 Biolabs 1 0 1 0 2.00 20/20 Biolabs Competitors 1766 7611 13064 777 2.55This is a breakdown of current ratings and recommmendations for 20/20 Biolabs and its competitors, as provided by MarketBeat.com. Given 20/20 Biolabs’ higher probable upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than its competitors. Net Margins Return on Equity Return on Assets 20/20 Biolabs N/A N/A N/A 20/20 Biolabs Competitors -5.52% -138.12% -0.39%Insider & Institutional Ownership58.0% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors.